Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Tiziana Pia Latiano, Emiliano Tamburini et al.|The Lancet Oncology|2020Cited by 322
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Chiara Cremolini, Daniele Rossini et al.|The Lancet Oncology|2022Cited by 268
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Fable Zustovich, Giuseppe Cabibbo et al.|Journal of Hepatology|2023Cited by 62
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classificationEnrico Caliman, Lorenzo Antonuzzo|Lung Cancer|2022Cited by 47